TENS device for Kidney Stones

Phase-Based Progress Estimates
Kidney Stones+2 MoreTENS - Device
18 - 70
All Sexes
What conditions do you have?

Study Summary

The investigators will assess the use of Transcutaneous Neurostimulation (TENS), a pharmacological alternative, for treatment of ureteral stent pain post-ureteroscopy. The primary aim for the investigators is to determine if use of a TENS unit will reduce post-operative pain and nausea associated with the ureteral stent. Secondary aim will be to assess if it can help minimize narcotic use.

Eligible Conditions
  • Kidney Stones

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 3-10 days

3-10 days
Pain on 11-point Visual Analog Score scale for each day until Ureteral Stent removed

Trial Safety

Trial Design

2 Treatment Groups

Standard care
1 of 2
TENS device
1 of 2

Active Control

Experimental Treatment

60 Total Participants · 2 Treatment Groups

Primary Treatment: TENS device · No Placebo Group · N/A

TENS device
Experimental Group · 1 Intervention: TENS · Intervention Types: Device
Standard careNoIntervention Group · 1 Intervention: Standard care · Intervention Types:
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 2

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 3-10 days

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,164 Previous Clinical Trials
35,687,688 Total Patients Enrolled
Simon Conti, MDPrincipal InvestigatorStanford University

Eligibility Criteria

Age 18 - 70 · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
have a low but finite risk of developing a post-procedure ureteral complication
are 50% less likely to experience a complication than those not receiving a stent

Who else is applying?

What state do they live in?
How old are they?
18 - 65100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria100.0%